Brigham Young University researchers recently developed a new anticoagulation strategy for use during extracorporeal circulation (ECC) that does not involve systemic administration of heparin, which causes negative reactions in three to 10 percent of surgical patients. "Rather than give something to the patient to prevent coagulation, let's take something out," says BYU biomedical engineer Kenneth A. Solen, who led the study published in the August issue of ASAIO Journal (the journal of the American Society for Artificial Internal Organs).Solen’s team inhibited coagulation by absorbing plasma clotting factors using protamine immobilized on a Sepharose matrix (PSM). In a porcine ex-vivo circuit, plasma was separated from blood via plasmapheresis, passed through a column containing PSM beads, and then returned. After 90 minutes, prothrombin time (PT) was prolonged more than 10 times the baseline and blood clotting Factors I (fibrinogen), II (prothrombin), VIII, and X were decreased more than 90 percent. This state was maintained for 2 ½ hours without any detectable adverse consequences. Within 60 minutes of ECC cessation, PT approached normal levels and hemostasis was restored.
For More readings: Take a look at here.
Source:
University Communications
Brigham Young University
No comments:
Post a Comment